Inhibition of hepatitis C virus infection by polyoxometalates.

Abstract

Hepatitis C virus (HCV) infects about 2% of the world population. The standard treatment of chronic HCV infection is still discontented because of the low sustained virological response rate. The development of new HCV antivirals is a healthcare imperative. We explored the potentials of polyoxometalates to inhibit HCV infection using newly developed HCVcc cell culture system. We found one polyoxometalate compound (named POM-12) can inhibit HCV infection at the nanomolar range while displayed little cytotoxicity. We showed that POM-12 inhibited pseudotyped HCV infection but had no effect on HCV RNA replication. Furthermore, we showed that POM-12 was virucidal and can disrupt HCV particles. Finally we demonstrated that POM-12 had no effect on the vesicular stomatitis virus infection while had weak inhibitory activity against the influenza virus infection. In conclusion, we identified a potent anti-HCV compound which may provide an attractive drug candidate to cure HCV infection.

• Authors: Yue Qi, Yu Xiang, Juan Wang, Yanfei Qi, Juan Li, Junqi Niu, Jin Zhong
• Journal: Antiviral research (Antiviral Res) Vol. 100 Issue 2 Pg. 392-8 (Nov 2013) ISSN: 1872-9096 [Electronic] Netherlands
• PMID: 24025401 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier B.V. All rights reserved.

Chemical References

• Antiviral Agents
• Tungsten Compounds
• polyoxometalate I

Topics

• Antiviral Agents (pharmacology)
• Cell Line
• Hepacivirus (drug effects)
• Humans
• Microbial Sensitivity Tests
• Microbial Viability (drug effects)
• Orthomyxoviridae (drug effects)
• Tungsten Compounds (pharmacology)
• Vesiculovirus (drug effects)
• Virus Internalization (drug effects)
• Virus Replication (drug effects)